GHRP-2 vs GHRP-6 vs Ipamorelin: Potency, Appetite and Side Effects Compared

Comparing GHRP-2, GHRP-6, and ipamorelin is different from comparing most growth hormone peptides, because all three are the same kind of molecule: ghrelin mimetics that act on one shared receptor. They are not three different mechanisms competing against each other — they are three points on a single gradient that trades potency and appetite against selectivity.

At one end sits GHRP-6, the original and the "hungriest." In the middle sits GHRP-2, the most potent for raising growth hormone. At the clean end sits ipamorelin, which releases growth hormone with almost no cortisol, prolactin, or appetite. None of the three is FDA-approved as a therapy, and the 2026 reclassification of compounded peptides is now splitting them along the same line their pharmacology already drew. This guide walks through how they differ on potency, side effects, evidence, legal status, and — because most of what is sold online is unregulated — how to verify what you are actually buying. These are growth hormone peptides for research discussion, not medical advice.

What's the difference between GHRP-2, GHRP-6, and ipamorelin?

GHRP-2, GHRP-6, and ipamorelin are three growth-hormone-releasing peptides that all act on the same receptor — the ghrelin receptor (GHS-R1a) — to trigger a pulse of the body's own growth hormone. Unlike the GHRH-analog peptides they are often confused with, such as sermorelin and tesamorelin, these three are ghrelin mimetics. They differ mainly by selectivity: GHRP-6 causes the most appetite and cortisol, GHRP-2 is the most potent, and ipamorelin is the cleanest, with minimal off-target effects. None is FDA-approved as a therapy.

The table below summarizes the three at a glance. The sections that follow explain each row — the prose is where the decision actually lives, not the table.

How do GHRP-2, GHRP-6, and ipamorelin work?

All three peptides work through the same mechanism: they bind the growth-hormone-secretagogue receptor (GHS-R1a) — the same receptor the hunger hormone ghrelin uses — on pituitary and hypothalamic cells, stimulating a pulse of growth hormone. The GHRPs came first. Endocrinologist Cyril Bowers synthesized GHRP-6 at Tulane University in the early 1980s, then the more potent GHRP-2, years before ghrelin itself was discovered in 1999. Because each engages the receptor's downstream signaling slightly differently, their side-effect profiles diverge despite the shared target.

The history matters because it explains what these molecules are. Bowers was studying enkephalins — the body's natural painkiller peptides — when he noticed that certain modified versions made pituitary cells release growth hormone through a pathway no one had described. The receptor identified by Howard and colleagues in 1996 turned out to be an orphan receptor with no known natural ligand, which Bowers correctly predicted the body must possess. That prediction was confirmed when Kojima and colleagues identified ghrelin — a growth-hormone-releasing peptide made in the stomach — in 1999. In other words, these synthetic "keys" were discovered before anyone found the natural lock. Bowers later titled a paper on exactly this point: the unnatural growth-hormone-releasing peptide had begotten natural ghrelin.

For the comparison, two mechanistic facts carry most of the weight. First, all three are subject to the same brake: somatostatin, the body's GH "off switch," still limits the response, which is why these peptides do not push growth hormone to the runaway levels possible with injected HGH. Second, although the three share the GHS-R1a target, they bias its signaling differently — GHRP-2 raises intracellular cAMP and synergizes strongly with GHRH, while GHRP-6 more heavily engages the hypothalamic appetite circuitry. Those differences in downstream signaling, not differences in the receptor, are what separate the three compounds. The individual mechanisms are covered in more depth in the science guides for GHRP-6, GHRP-2, and ipamorelin. For how this ghrelin-mimetic class compares with the GHRH-analog peptides, see the companion comparison of ipamorelin vs sermorelin vs tesamorelin.

How do GHRP-2, GHRP-6, and ipamorelin compare on potency and side effects?

On potency and side effects, the three peptides form a clear gradient. GHRP-2 produces the highest peak growth hormone release of the three, GHRP-6 the strongest appetite stimulation, and ipamorelin the cleanest profile, with minimal cortisol, prolactin, or hunger. All three plateau near a saturation dose of about 1 mcg/kg, beyond which extra peptide raises cortisol and prolactin without adding growth hormone. The practical trade-off is potency and appetite versus selectivity — which is exactly what separates these otherwise similar compounds.

That saturation point is worth understanding before anything else, because it is where most dosing mistakes happen. Past roughly 1 mcg/kg, the growth hormone response flattens while the off-target effects keep climbing, so "more" does not mean a bigger GH pulse — it mostly means more cortisol and prolactin. This ceiling applies to all three compounds and is one reason careful protocols favor modest, repeated doses over large ones.

Which releases the most growth hormone?

GHRP-2 releases the most growth hormone of the three. In a controlled human study, Arvat and colleagues found that GHRP-2 produced GH responses exceeding even a maximal dose of growth-hormone-releasing hormone (Arvat et al., 1997, Peptides), with the effect being dose-dependent up to about 1–2 mcg/kg before plateauing. GHRP-6 and ipamorelin produce robust but somewhat lower peak responses, roughly comparable to each other. This is a human-pharmacology finding: the peptides reliably raise growth hormone, which is well established, even though durable outcomes from that GH rise are not.

Which causes the most appetite, cortisol, and prolactin?

Ipamorelin causes the fewest off-target effects of the three. GHRP-6 produces intense hunger — the strongest of any GHRP — by engaging appetite-driving NPY/AgRP neurons in the hypothalamus, the same circuit ghrelin uses, plus the most cortisol and prolactin at higher doses. GHRP-2 sits in the middle: it raises appetite (human studies show it increases food intake, though less than GHRP-6) and produces moderate cortisol and prolactin. The same Arvat study found that GHRP-2's cortisol and ACTH response was comparable to a dose of corticotropin-releasing hormone — in the authors' words, the peptide is "not fully specific."

Ipamorelin is the exception that defines the gradient. In the foundational preclinical study, Raun and colleagues showed that ipamorelin released growth hormone with no rise in ACTH or cortisol even at doses more than 200 times its GH-releasing dose (Raun et al., 1998, European Journal of Endocrinology) — selectivity demonstrated in animal models. Whether the appetite stimulation of GHRP-6 is a drawback or a feature depends entirely on the goal: it is unwanted for most users but can be deliberately useful during a bulking phase.

What does the research actually show for each?

Human outcome evidence is limited for all three, and none is FDA-approved as a therapy. GHRP-2 has the most clinical data — it is approved in Japan as a diagnostic agent (pralmorelin) for growth hormone deficiency — but its development as a growth treatment did not succeed, and it survives only as a diagnostic. GHRP-6's deepest evidence is preclinical, including cardioprotection research. Ipamorelin's selectivity rests on preclinical work. Across all three, the pharmacology is well-characterized; durable human outcome data is not.

GHRP-2 is the most instructive case, because it went furthest and still did not become a therapy. After the human pharmacology was established, an intranasal formulation was developed and studied for childhood growth, but the therapeutic program was discontinued without approval — increasing endogenous GH secretion did not reliably translate into the sustained growth benefit a treatment would need. What remained was its value as a provocative test: a single injection raises plasma GH above a threshold in healthy people but not in those with severe deficiency, which is the basis of its Japanese diagnostic approval. That is a genuine clinical use, but it is a long way from the body-composition and anti-aging claims attached to GHRP-2 online.

GHRP-6's most interesting modern research has little to do with growth hormone at all. Beyond GHS-R1a, it interacts with the CD36 scavenger receptor, and preclinical work — much of it from Cuban researchers, with some early human safety data — has examined its ability to protect heart and other tissue from ischemic damage. This is a real and active line of investigation, but it is preclinical-to-early-clinical and separate from the performance uses most buyers have in mind. Ipamorelin, for its part, has the thinnest human record: its defining selectivity is well-documented preclinically, with limited human outcome data. The honest summary across all three is that these are well-characterized pharmacological tools whose long-term human benefits and risks have not been established in trials. This gap between solid pharmacology and thin outcome data is one academic specialists have flagged: Eileen Kennedy, a peptide-therapeutics chemist at the UNC Eshelman School of Pharmacy quoted in 2026 reporting on the reclassification, has emphasized that the human trial evidence behind many of the most popular grey-market peptides remains thin.

Which should you choose for your goal? (and can you stack them?)

Goal determines the best fit. Choose GHRP-6 when appetite stimulation is wanted, such as bulking phases; GHRP-2 for the highest peak growth hormone with more manageable appetite; and ipamorelin when a clean GH pulse with minimal cortisol, prolactin, or hunger is the priority. In practice, any of the three is often paired with a GHRH analog such as CJC-1295, because a ghrelin mimetic and a GHRH analog act on different receptors and produce a larger combined pulse than either alone — and this should only be done under medical supervision.

For most people researching general GH support — sleep, recovery, body composition — ipamorelin's clean profile is the reason it has become the default of the three; the absence of appetite spikes and cortisol elevation makes it the easiest to use without unwanted effects. GHRP-2 is the choice when peak GH output is the explicit priority and its moderate appetite stimulation is acceptable. GHRP-6 occupies a narrower niche: its intense hunger is a liability for cutting or recomposition but a genuine tool when the goal is eating in a surplus.

Can you stack a GHRP with CJC-1295?

Yes. A GHRP (or ipamorelin) and a GHRH analog such as CJC-1295 act on two different receptors, and combining them produces a larger, synergistic growth hormone pulse than either alone — a synergy documented in human studies going back to Bowers' early work. The most common pairing is CJC-1295 with ipamorelin, precisely because ipamorelin contributes the GHS-R1a signal without adding cortisol or appetite. The CJC-1295 and ipamorelin dosing calculator and the CJC-1295 and ipamorelin stack protocol guide cover timing and reconstitution, and the broader peptide stacking guide explains why receptor-complementary pairs work while stacking two ghrelin mimetics together generally does not add benefit.

What's the legal and regulatory status of each?

The three peptides are now splitting along regulatory lines that mirror their pharmacology. All three were placed on the FDA's Category 2 restricted-compounding list in 2023. Ipamorelin was removed and referred to the Pharmacy Compounding Advisory Committee, moving toward Category 1 — legally compoundable with a prescription — while GHRP-2 and GHRP-6 are expected to remain restricted, specifically because of their cortisol and prolactin elevation. GHRP-2 is additionally approved in Japan as a diagnostic agent; none is FDA-approved; all three are WADA-prohibited under section S2. Verify current status before relying on it, as the formal list is still being finalized.

The detail worth sitting with is that the regulatory split is the pharmacological split. The same selectivity that makes ipamorelin the "cleanest" of the three is the reason it is being routed back toward compounding eligibility, while the cortisol- and prolactin-raising GHRPs are the ones flagged to stay restricted. Coming off Category 2 does not mean ipamorelin is FDA-approved — "Category 1," "FDA-approved," and "research-use-only gray market" remain three distinct statuses, and most ipamorelin sold online is still in the unregulated research-chemical channel. Reporting on the reclassification has not been unanimous: at least one source has suggested ipamorelin could face continued restriction pending committee review, so the safest reading is that the direction is set but the formal FDA list governs.

GHRP-2's regulatory history is unique among the three for a different reason: it is the only one approved anywhere. Marketed as pralmorelin (brand name GHRP Kaken) by Kaken Pharmaceutical, it received Japanese approval in 2004 as a diagnostic test for growth hormone deficiency. GHRP-6 has never been approved in any country. For athletes, the distinction is moot — the WADA Prohibited List bans growth hormone secretagogues under section S2, so all three are prohibited in and out of competition.

How do you verify the GHRP-2, GHRP-6, or ipamorelin you're buying is real?

Most GHRP-2, GHRP-6, and ipamorelin sold online is unregulated research material, and because the three are structurally similar and cheap to mislabel as one another, identity verification matters as much as purity. Demand a recent third-party certificate of analysis (CoA) showing HPLC purity for the specific compound, plus mass-spectrometry (MS) identity confirmation by molecular weight — HPLC alone cannot tell one hexapeptide from another. Cross-check the shop and compound against independent lab-test data before ordering, and treat a missing or unverifiable certificate as a red flag.

This is not a hypothetical concern for these particular peptides. GHRP-2 and GHRP-6 are both hexapeptides of similar molecular weight, hexarelin is another close relative, and ipamorelin is a pentapeptide — all are members of one structural family, and a vial labeled as one could contain another, or a blend, or an under-filled dose. An HPLC chromatogram showing 99% purity confirms the sample is mostly one compound, but only mass spectrometry confirms which compound by matching its molecular weight. A complete CoA pairs both, which is why the guides on HPLC purity testing and mass-spectrometry identity testing both apply here. For ipamorelin specifically, the where to buy ipamorelin guide walks these checks through to sourcing; no equivalent guide exists yet for GHRP-2 or GHRP-6, so apply the same certificate and identity standards when sourcing those.

Independent platform data is useful precisely because Peptigrity does not sell peptides. Across the platform's independent lab-test database — currently more than 8,600 HPLC purity tests across 365 tracked shops (verified June 2026) — the three compounds show a revealing pattern. Ipamorelin has accumulated 304 independent HPLC tests at a 99.7% average purity, while GHRP-6 has 27 tests at 99.3% and GHRP-2 has 26 tests at 99.2% (verified June 2026). The purity figures are broadly similar, but the test volumes are not: ipamorelin has been submitted for testing more than ten times as often as either GHRP individually. Even within this single drug class, buyer demand has consolidated around the selective compound — the same one the regulators are routing back toward legality. These averages reflect samples shops chose to submit, which skews toward higher-confidence products, so treat them as directional rather than a guarantee for any single vial.

Frequently Asked Questions

What is the difference between GHRP-2 and GHRP-6?

They share the same receptor (GHS-R1a) and the same basic mechanism, but GHRP-2 is more potent for growth hormone and cleaner on appetite, while GHRP-6 causes the strongest hunger of any GHRP and more cortisol at higher doses. GHRP-2 was developed as a structural refinement of GHRP-6 specifically to raise potency and reduce side effects. For maximum GH with manageable appetite, GHRP-2 is the usual pick; for deliberate appetite stimulation, GHRP-6.

Which GHRP is best for bulking?

GHRP-6, because its strong appetite stimulation supports eating in a caloric surplus — the hunger that is a drawback for most goals becomes useful when the aim is to eat more. Ipamorelin is the opposite choice when appetite is unwanted, and GHRP-2 sits in between. Bear in mind that none of these is a substitute for training and nutrition, and appetite stimulation is a behavioral effect, not muscle growth itself.

Which is the cleanest or safest of the three?

Ipamorelin. It raises little to no cortisol or prolactin and produces minimal appetite — the selectivity demonstrated in preclinical studies at doses far above its GH-releasing threshold. That same clean profile is why it is being routed back toward Category 1 compounding eligibility while GHRP-2 and GHRP-6, which elevate cortisol and prolactin, are expected to remain restricted. "Cleaner" is not the same as "risk-free," and human long-term data is still limited.

Can you stack GHRP-2, GHRP-6, or ipamorelin with CJC-1295?

Yes. A ghrelin mimetic and a GHRH analog act on different receptors and combine for a larger growth hormone pulse than either alone, which is why CJC-1295 paired with ipamorelin is one of the most common GH-peptide protocols. Stacking two ghrelin mimetics together (for example GHRP-2 with GHRP-6) generally does not add benefit, since they compete at the same receptor. Any stack should involve medical supervision and IGF-1 monitoring.

Are GHRP-2, GHRP-6, or ipamorelin FDA-approved?

No — none is FDA-approved. GHRP-2 is approved in Japan as a diagnostic agent (pralmorelin) for assessing growth hormone deficiency, but not as a treatment. Ipamorelin was removed from the FDA's Category 2 restricted list and referred for review, moving toward legal compounding under prescription, while GHRP-2 and GHRP-6 are expected to remain restricted. Compounding eligibility is not the same as FDA approval.

Why does GHRP-6 make you so hungry?

GHRP-6 strongly activates appetite-driving NPY/AgRP neurons in the hypothalamus by mimicking ghrelin, the body's hunger hormone — the same receptor pathway that signals hunger before meals. This orexigenic effect is much weaker with GHRP-2 and minimal with ipamorelin, which is one of the main practical differences between the three. The hunger typically appears within a short time of injection and is dose-related.

This article is for educational and informational purposes only and does not constitute medical advice. The peptides discussed are not FDA-approved for the uses described and are largely unregulated research compounds; GHRP-2 is approved only as a diagnostic agent in Japan. Always consult a qualified healthcare provider before using any peptide or research compound. All three compounds are prohibited in sport under the WADA Prohibited List. Peptigrity is an independent review platform and does not sell, endorse, or recommend specific products or vendors.